Patients with triple receptor-negative breast cancer often develop aggressive metastatic disease, which also might involve the brain. In many cases, systemic and local treatment is needed. It is important to consider the toxicity of chemo- and radiotherapy, especially when newly approved drugs become available. Randomised studies leading to drug approval often exclude patients with newly diagno...

BACKGROUND Primary central nervous system lymphoma (PCNSL) rarely relapses in extracranial sites, and no specialized guidelines for follow-up evaluation have been proposed. METHODS We analyzed 65 patients with newly diagnosed PNCSL to evaluate the pattern of relapse and prognostic factors. RESULTS Of the 65 patients analyzed, 55 had only parenchymal brain disease, and 10 had both intracrani...

The benefit and risk of whole brain radiation therapy (WBRT) compared to locally limited radiation therapy was assessed in 61 patients with solitary brain metastases from non-small cell lung cancer without an unresectable active primary lesion or systemic dissemination in the other organs. Twenty-three patients received local irradiation (Group A), and 38 patients received whole brain irradiati...

We retrospectively analyzed patients with brain metastasis from lung cancer to evaluate treatment modalities for metastatic brain tumors and to devise criteria for individualized treatment plans. Between October, 1986 and December, 1994, 90 patients were selected for this study. The majority (67.8%) received whole-brain radiotherapy (WBRT) alone. WBRT following surgical removal was carried out ...

Brain metastases are a common complication of non-small cell lung cancer (NSCLC). Prognosis is poor and the effectiveness of whole brain radiotherapy (WBRT) is uncertain for patients with moderate performance status. Studies on WBRT effectiveness have thus far used outcome measures, such as survival, performance status and cognitive function. The aim of this study was to study what patients wit...

The prognosis associated with brain metastasis arising from breast cancer is very poor. Eribulin is a microtubule dynamic inhibitor synthesized from halichondrin B, a natural marine product. In a phase III study (EMBRACE), eribulin improved overall survival in patients with heavily pretreated metastatic breast cancers. However, these studies included few patients with brain metastases. Metastat...

Stereotactic radiosurgery (SRS) has become a widely available treatment option for patients with brain metastases. Recent clinical trials suggest that SRS can be used without upfront whole brain radiotherapy (WBRT), resulting in several clinical dilemmas in the current daily practice of SRS. The proper patient selection for SRS or WBRT continues to evolve. Statistical models to predict when new...

Non-small cell lung cancer (NSCLC) constitutes approximately 85% of all lung cancers, with the majority of patients having advanced disease at presentation. Between 10-20% present with brain metastases (BM) and up to 40% of patients will develop BM. The overall median survival is reported to average three to four months if treated with whole brain radiotherapy (WBRT) alone. Management of BM pat...